Table of Contents Chapter 1 General introduction and thesis outline 9 Outline of this thesis 16 Part 1 PD-1T TILs as precision and clinical applicable biomarker in NSCLC Chapter 2 PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC 25 Supplemental Material 57 Chapter 3 Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in nonsmall cell lung cancer 81 Supplemental material 107 Chapter 4 A dysfunctional T cell gene signature for predicting nonresponse to PD‑1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics 129 Supplemental material 153 Part 2 Serum and pleural effusion as bio-sources for diagnostic biomarker tests Chapter 5 A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors 171 Supplemental material 194 Chapter 6 Cell-free DNA in the supernatant of pleural effusion can detect driver and resistance mutations and can guide TKI treatment decisions 211 Supplemental material 222 Part 3 Summary and future perspectives Chapter 7 Summary and future perspectives 233 Chapter 8 Nederlandse samenvatting 251 Appendices Chapter 5 Supplemental material: Methods 263 Chapter 2 Commentary by Anagnostou V and Luke JJ in Clinical Cancer Research 279 List of publications 287 Curriculum Vitae 293 Dankwoord 297
RkJQdWJsaXNoZXIy MTk4NDMw